Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

HIV Vaccine Awareness Day

Published: Thursday, May 22, 2014
Last Updated: Thursday, May 22, 2014
Bookmark and Share
Early stage vaccine clinical trials are expected to begin in South Africa in early 2015.

Developing a safe and sufficiently effective HIV vaccine is essential if we are to achieve a timely and durable end to the global HIV/AIDS pandemic. The path to an HIV vaccine has not been-and will not be-an easy one.

In the 27 years since the first HIV vaccine clinical trial was performed, we have been disappointed by many promising investigational vaccines that ultimately proved ineffective in clinical trials, encouraged by a large-scale study in Thailand that demonstrated for the first time that an HIV vaccine can provide a modest level of protection, and, heartened by recent important discoveries about antibodies that may be capable of protecting against a wide range of HIV strains.

HIV is uniquely challenging as a vaccine target because, unlike other viruses, it elicits antibodies capable of killing a wide range of HIV strains (called broadly neutralizing antibodies) in only a minority of those who become infected and only after several years of infection. Furthermore, HIV is also extremely genetically diverse and mutates rapidly to evade immune responses.

But through important basic research discoveries, scientists have made substantial progress in understanding how broadly neutralizing HIV antibodies develop and the specific sites on the virus to which they bind, which will lead to promising new targets for future HIV vaccine candidates.

For example, NIAID scientists and grantees, using blood samples from a newly HIV-infected person, were able to chart the co-evolution of the virus and the antibodies created in response to infection. In the past year, researchers have highlighted the regions of HIV where these antibodies bind to block infection and revealed the structure of the HIV protein that is responsible for allowing HIV to enter human immune cells and cause infection.

They also found the mechanism responsible for stabilizing key HIV proteins and hiding sites where some of the most powerful HIV neutralizing antibodies attach themselves and conducted a vaccine study in nonhuman primates using a simian version of HIV (SIV) that yielded insights into controlling and clearing infection.

Additionally, scientists have also made advances in understanding T-cell responses that may be important to vaccine-induced immunity against HIV. By applying insights gained from each of these discoveries, researchers may be able to develop a vaccine that mimics the natural development of antibodies but creates them rapidly enough to prevent HIV infection.

NIAID researchers are currently evaluating the intravenous administration of a broadly neutralizing antibody called VRC 01 in early-stage trials in both HIV-infected and uninfected adults. If the two studies indicate that the approach is safe and can block the virus, NIAID may evaluate the antibody in clinical trials involving a larger number of adults and infants born to HIV-infected mothers who did not receive prenatal care or antiretroviral therapy to prevent mother-to-child HIV transmission.

Scientists also continue to explore findings from the RV 144 HIV vaccine study in Thailand, which, in 2009, provided the first evidence that an HIV vaccine can provide a modest level of protection. For example, looking at serum samples collected from participants in the Thai trial, investigators have identified previously unrecognized attributes of the antibodies that apparently reduced the risk of HIV infection among the study participants who received the investigational vaccine regimen. Researchers are working to improve and prolong the level of protection experienced in the study by using an extra vaccine boost and improved adjuvants to increase antibody durability.

On this HIV Vaccine Awareness Day, NIAID thanks the thousands of men and women who have participated in HIV vaccine clinical trials and the researchers, clinicians, and nurses who continue to work to find an effective vaccine. We may not have an effective HIV vaccine, but the breadth of knowledge we have gained through animal and human clinical trials and painstaking basic research lend hope that a successful vaccine is not beyond our reach. NIAID remains committed to the important research needed to find the vaccine that will ultimately help end the global HIV/AIDS pandemic.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Saturday, July 25, 2015
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
Tuesday, July 21, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Tuesday, July 21, 2015
NIH-funded Vaccine for West Nile Virus Enters Human Clinical Trials
Enrollment is expected to be completed by December 2015.
Tuesday, July 07, 2015
In Blinding Eye Disease, Trash-Collecting Cells Go Awry, Accelerate Damage
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Friday, July 03, 2015
Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age
NIH-funded study is the first look at antipsychotic prescriptions patterns in the U.S.
Thursday, July 02, 2015
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Friday, June 26, 2015
NIH Begins Clinical Trial of New Medication for Alcohol Use Disorder
Clinical trial will evaluate the safety and effectiveness of gabapentin enacarbil in treating alcohol use disorder.
Friday, June 26, 2015
Study of Ebola Survivors Opens in Liberia
Trial to examine long-term health effects of Ebola virus disease.
Friday, June 19, 2015
NIH Names Walter J. Koroshetz, M.D. Director of the NINDS
Dr. Collins recognized Dr. Koroshetz’ role in the creation of the StrokeNet.
Saturday, June 13, 2015
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Tuesday, June 09, 2015
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
Wednesday, June 03, 2015
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Thursday, May 28, 2015
Two Treatments Yield Similar Results for Children After Cardiac Arrest
NIH-funded research finds therapeutic hypothermia no more effective than normal temperature control.
Friday, May 08, 2015
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!